Rhygaze
Developer of optogenetic-based gene therapy approaches for vision restoration. The organization combines optogenetic protein engineering and gene delivery tools to install light-sensing function into target retinal cell types and advances programs from preclinical assay development through clinical translation. Headquarters in Basel, Switzerland and Philadelphia, PA, USA.
Industries
Nr. of Employees
small (1-50)
Products
Optogenetic gene therapy platform for retinal photosensitization
A platform combining optogenetic proteins with gene delivery tools to confer light sensitivity to target retinal cell types for vision restoration.
Optogenetic gene therapy platform for retinal photosensitization
A platform combining optogenetic proteins with gene delivery tools to confer light sensitivity to target retinal cell types for vision restoration.
Services
Non-clinical assay development and IND-enabling studies to support clinical progression of ophthalmic gene therapies.
Clinical translation, regulatory submission preparation, and program-level management for gene therapy candidates in ophthalmology.
Non-clinical assay development and IND-enabling studies to support clinical progression of ophthalmic gene therapies.
Clinical translation, regulatory submission preparation, and program-level management for gene therapy candidates in ophthalmology.
Expertise Areas
- Optogenetic therapy development
- Retinal gene therapy
- Clinical translation of gene therapies
- Preclinical assay development and IND-enabling studies
Key Technologies
- Optogenetics
- Gene delivery vectors (AAV-mediated delivery)
- Preclinical assay development
- IND-enabling study design
News & Updates
Multiple team members were instrumental in the development, regulatory approval, and commercialization of a landmark retinal gene therapy that was the first gene therapy product approved by the U.S. FDA for a genetic disease.
Multiple team members were instrumental in the development, regulatory approval, and commercialization of a landmark retinal gene therapy that was the first gene therapy product approved by the U.S. FDA for a genetic disease.